- Pfizer stock soared as much as 15% on Monday after the company announced its coronavirus vaccine succeeded in final-stage clinical trials.
- The US drugmaker's
vaccine is being developed with the German biotech firm BioNTech, whose shares soared 25% at intraday highs on the news. - The vaccine won't be immediately available, as it still needs to be reviewed by the US Food and Drug Administration.
- The companies said they expected to produce up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021.
Pfizer stock leapt as much as 15% on Monday after the drugmaker announced that its experimental COVID-19 vaccine succeeded in late-stage trials.
The US pharma firm said its vaccine, developed with a German biotech partner, BioNTech, was over 90% effective in preventing
"Today is a great day for science and humanity," Dr. Albert Bourla,
Pfizer said it would apply to the US Food and Drug Administration for emergency-use authorization — a step that would allow it to distribute the vaccine shot more widely. The approval request is contingent on additional safety data, which the company won't have until later in November.
Pfizer and BioNTech are the first drugmakers to post successful results from crucial trials of a COVID-19 vaccine.
Both the S&P 500 and the Dow Jones industrial average opened at intraday records following the news and stayed strongly higher throughout the morning.